Abciximab (Reopro, Abcixifiban): Difference between revisions

Latest revision as of 18:46, 9 May 2023

@@ Line 3: / Line 3: @@
 [[Category:Anticoagulant]]
 [[Category:Glycoprotein IIb/IIIa inhibitors]]
-'''Abciximab (Reopro, Abcixifiban)'''
-Abciximab, sold under the brand names Reopro and Abcixifiban, is a medication used to prevent blood clots in people undergoing coronary angioplasty. It is a glycoprotein IIb/IIIa inhibitor, which means that it blocks the platelets in the blood from aggregating and forming clots. This medication is administered intravenously during the procedure, usually in combination with heparin and aspirin.
-Abciximab was first approved by the United States Food and Drug Administration (FDA) in 1994 for use during coronary angioplasty. Since then, it has also been approved for use in preventing blood clots during other cardiovascular procedures, such as coronary artery bypass surgery and stent placement.
-Some common side effects of abciximab include bleeding, bruising, and low blood pressure. In rare cases, it can cause severe allergic reactions or blood clotting disorders.
-Overall, Abciximab has been found to be an effective medication in preventing blood clots during cardiovascular procedures. However, it should only be used under the guidance of a healthcare provider and with careful monitoring due to its potential side effects.
-==References==
-{{Reflist}}
-==External links==
-    [https://www.anesthesia.wiki/index.php/Abciximab_(Reopro,_Abcixifiban) Abciximab page on the Anesthesia Wiki]
-{{Pharmaceutical-drug-stub}}